Brecanavir: Interim Phase II data

Interim data from 24-week analysis of an open-label, 48-week Phase II trial (HPR10006) in 31 patients, 81% had plasma HIV-1 RNA below the level of detection of standard assays (<400 copies/mL) and 77%...